Full Product Name
C2 siRNA (Human)
Product Synonym Names
Complement C2; C3/C5 convertase
Product Gene Name
C2 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P06681
Specificity
C2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human C2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of C2 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
C2 sirna
siRNA to inhibit C2 expression using RNA interference
Applications Tested/Suitable for C2 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for C2. It may not necessarily be applicable to this product.
NCBI Accession #
NP_000054.2
[Other Products]
NCBI GenBank Nucleotide #
NM_000063.5
[Other Products]
UniProt Primary Accession #
P06681
[Other Products]
UniProt Secondary Accession #
O19694; Q13904; B4DPF3; B4DV20; E9PFN7[Other Products]
UniProt Related Accession #
P06681[Other Products]
Molecular Weight
69,444 Da
NCBI Official Full Name
complement C2 isoform 1 preproprotein
NCBI Official Synonym Full Names
complement component 2
NCBI Official Symbol
C2??[Similar Products]
NCBI Official Synonym Symbols
CO2; ARMD14
??[Similar Products]
NCBI Protein Information
complement C2
UniProt Protein Name
Complement C2
UniProt Synonym Protein Names
C3/C5 convertase
Protein Family
Complement C2
UniProt Gene Name
C2??[Similar Products]
UniProt Entry Name
CO2_HUMAN
NCBI Summary for C2
Component C2 is a serum glycoprotein that functions as part of the classical pathway of the complement system. Activated C1 cleaves C2 into C2a and C2b. The serine proteinase C2a then combines with complement factor 4b to create the C3 or C5 convertase. Deficiency of C2 has been reported to associated with certain autoimmune diseases and SNPs in this gene have been associated with altered susceptibility to age-related macular degeneration. This gene localizes within the class III region of the MHC on the short arm of chromosome 6. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Additional transcript variants have been described in publications but their full-length sequence has not been determined.[provided by RefSeq, Mar 2009]
UniProt Comments for C2
C2: Component C2 which is part of the classical pathway of the complement system is cleaved by activated factor C1 into two fragments: C2b and C2a. C2a, a serine protease, then combines with complement factor 4b to generate the C3 or C5 convertase. Defects in C2 are the cause of complement component 2 deficiency (C2D). A deficiency of the complement classical pathway associated with the development of autoimmune disorders, mainly systemic lupus erythematosus. Skin and joint manifestations are common and renal disease is relatively rare. Patients with complement component 2 deficiency are also reported to have recurrent or invasive infections. Belongs to the peptidase S1 family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Secreted; Secreted, signal peptide; Protease; EC 3.4.21.43
Chromosomal Location of Human Ortholog: 6p21.3
Cellular Component: extracellular space; extracellular region
Molecular Function: metal ion binding; serine-type endopeptidase activity
Biological Process: regulation of complement activation; innate immune response; proteolysis; complement activation, classical pathway; response to nutrient; complement activation
Disease: Macular Degeneration, Age-related, 14; Complement Component 2 Deficiency
Research Articles on C2
1. The C2 and CFB gene variants were shown to be associated with polypoidal CNV. Typical PCV was not associated with variants in these genes.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
